Tara Heitner
New IR power at Cyxone
In June, the biotechnology company Cyxone announced a change in management – Carl-Magnus Högerkorp stepped down from his role as Chief...
New management at Cyxone
The board of directors of Malmö-based Cyxone recently announced that they...
Cyxone focuses on the RA program
First North-listed Cyxone recently published its Q1 report, a...
News roundup Friday, April 29
WntResearch
Cyxone on the progress of the T20K project
Biotech company Cyxone recently announced the next step in the T20K project,...
Cyxone is investing in Phase IIb with an issue
Despite a range of existing therapies for rheumatoid arthritis...
Cyxone prepares for the start of the phase IIb study
Biotechnology company Cyxone is about to launch a...
Cyxone's CRO agreement shows that the Phase IIb study in RA is progressing according to plan
In preparation for the upcoming phase IIb study with...
BioStock Studio: Cyxone comments on the results of the covid-19 study
Biotech company Cyxone has presented results from its phase...
Eight CEOs on their expectations for BIO-Europe
These days it is time again for BIO-Europe,...
Cyxone has completed recruitment in the Phase II study in COVID-19
Swedish biotechnology company Cyxone announced last month...
Cyxone explores new treatment options for T20K
After identifying new potential treatment options for...